3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
24
Neoplasm Metastasis
6
Colonic Neoplasms
6
Stomach Neoplasms
5
Rectal Neoplasms
5
Carcinoma, Hepatocellular
4
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Unresectable Metastatic Colorectal Cancer
2
Recurrence
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Adenocarcinoma
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Ovarian Neoplasms
1
Oligometastatic Gastric Adenocarcinoma
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Margins of Excision
1
Lung Neoplasms
1
Locally-advanced Rectal Cancer
1
Locally Advanced Colorectal Carcinoma
1
Hyperthermia
1
Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Adenocarcinoma
1
Gallbladder Neoplasms
1
Interventions
Gemcitabine
7
Oxaliplatin
6
Cisplatin
5
durvalumab
3
130-nm albumin-bound paclitaxel
3
pembrolizumab
2
Leucovorin
2
Drug Therapy
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
sintilimab
1
pertuzumab
1
anlotinib
1
Trastuzumab
1
Taxes
1
Standard of Care
1
Platinum
1
Observation
1
Nivolumab
1
Neoadjuvant Therapy
1
Long-Term Synaptic Depression
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
Everolimus
1
Commerce
1
Cholangiopancreatography, Endoscopic Retrograde
1
Biopsy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Gallbladder Neoplasms
×
Folfox protocol
×
Clear all
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled